Literature DB >> 33614561

Atypical Presentations of IPEX: Expect the Unexpected.

Filippo Consonni1, Sara Ciullini Mannurita2, Eleonora Gambineri2,3.   

Abstract

Immune dysregulation, polyendocrinopathy, and enteropathy, X-linked (IPEX) syndrome is a rare disorder that has become a model of monogenic autoimmunity. IPEX is caused by mutations in FOXP3 gene, a master regulator of regulatory T cells (Treg). Cases reported in the last 20 years demonstrate that IPEX clinical spectrum encompasses more than the classical triad of early-onset intractable diarrhea, type 1 diabetes (T1D) and eczema. Atypical cases of IPEX include patients with late-onset of symptoms, single-organ involvement, mild disease phenotypes or rare clinical features (e.g., atrophic gastritis, interstitial lung disease, nephropathy etc.). Several atypical presentations have recently been reported, suggesting that IPEX incidence might be underestimated. Immunosuppression (IS) treatment strategies can control the disease, however at the moment allogeneic hematopoietic stem cell transplantation (HSCT) is the only available definitive cure, therefore it is important to achieve a prompt diagnosis. This review aims to describe unusual clinical phenotypes, beyond classical IPEX. Overall, our analysis contributes to increase awareness and finally improve diagnosis and treatment intervention in IPEX in order to ensure a good quality of life.
Copyright © 2021 Consonni, Ciullini Mannurita and Gambineri.

Entities:  

Keywords:  FOXP3; IPEX; immune dysregulation; primary immunodeficiencies; regulatory T cells

Year:  2021        PMID: 33614561      PMCID: PMC7892580          DOI: 10.3389/fped.2021.643094

Source DB:  PubMed          Journal:  Front Pediatr        ISSN: 2296-2360            Impact factor:   3.418


  8 in total

1.  Immune dysregulation, polyendocrinopathy and enteropathy, X-linked (IPEX) syndrome due to a mutation in FOXP3, modified by a pathogenic variant in SON (SON DNA-binding protein).

Authors:  Ranjit I Kylat; Kelly Stanley; Sarah Simon; Robert P Erickson
Journal:  J Appl Genet       Date:  2022-09-30       Impact factor: 2.653

2.  Case Report: Atypical Manifestations Associated With FOXP3 Mutations. The "Fil Rouge" of Treg Between IPEX Features and Other Clinical Entities?

Authors:  Micaela Gentile; Maurizio Miano; Paola Terranova; Stefano Giardino; Maura Faraci; Filomena Pierri; Enrico Drago; Daniela Verzola; Gianmarco Ghiggeri; Enrico Verrina; Andrea Angeletti; Barbara Cafferata; Alice Grossi; Isabella Ceccherini; Gianluca Caridi; Francesca Lugani; Lorenzo Nescis; Enrico Fiaccadori; Luca Lanino; Daniela Fenoglio; Edoardo La Porta
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

3.  Clinical and immunological characteristics of five patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome in China-expanding the atypical phenotypes.

Authors:  Yu Huang; Shuyu Fang; Ting Zeng; Junjie Chen; Lu Yang; Gan Sun; Rongxin Dai; Yunfei An; Xuemei Tang; Ying Dou; Xiaodong Zhao; Lina Zhou
Journal:  Front Immunol       Date:  2022-08-24       Impact factor: 8.786

Review 4.  Towards gene therapy for IPEX syndrome.

Authors:  Simon Borna; Esmond Lee; Yohei Sato; Rosa Bacchetta
Journal:  Eur J Immunol       Date:  2022-04-13       Impact factor: 6.688

Review 5.  Familial Clustering of Juvenile Psoriatic Arthritis Associated with a Hemizygous FOXP3 Mutation.

Authors:  Raed Alzyoud; Shahad Alansari; Heba Maaitah; Haya AlDossari; Dorota Monies; Sulaiman M Al-Mayouf
Journal:  Curr Rheumatol Rep       Date:  2021-07-03       Impact factor: 4.592

Review 6.  IL-2 Signaling Axis Defects: How Many Faces?

Authors:  Filippo Consonni; Claudio Favre; Eleonora Gambineri
Journal:  Front Pediatr       Date:  2021-07-02       Impact factor: 3.418

7.  Autoimmune Cytopenias and Dysregulated Immunophenotype Act as Warning Signs of Inborn Errors of Immunity: Results From a Prospective Study.

Authors:  Ebe Schiavo; Beatrice Martini; Enrico Attardi; Filippo Consonni; Sara Ciullini Mannurita; Maria Luisa Coniglio; Marco Tellini; Elena Chiocca; Ilaria Fotzi; Laura Luti; Irene D'Alba; Marinella Veltroni; Claudio Favre; Eleonora Gambineri
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

Review 8.  ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.

Authors:  Filippo Consonni; Eleonora Gambineri; Claudio Favre
Journal:  Ann Hematol       Date:  2022-01-20       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.